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Since its inception as a specialist discipline, inter- 
ventional cardiology has been and still is preoccupied 
with the achievement of a greater understanding and 
ultimately control of the biologic healing process af- 
ter percutaneous transluminal coronary angioplasty 
(PTCA),l? 2 the apparent enigma of “restenosis.” In- 
troduction and application of a wide variety of alter- 
native and adjunctive treatment modalities (endo- 
luminal coronary stent implantation,3 directional, 
extractional, or rotationa14-6 atherectomy, laser bal- 
loon angioplasty,7 and laser angioplasty8T g and a wide 
variety of pharmacologic agents have, thus far, failed 
to suppress this ubiquitous processlo-l6 
Proceeding with trepidation through the veritable 
jungle of already available and rapidly proliferating 
literature on this subject, it is noteworthy that there 
are perhaps only three observations that are univer- 
sally held: (1) the attribution of initiation of percu- 
taneous coronary intervention to Dr. Andreas Gru- 
entzig; (2) that this approach to therapy of coronary 
artery obstructions has become “widely accepted” 
despite that its inaugural use was only in September 
1977r7; and notwithstanding (3) the apparently ines- 
capable biologic phenomenon of restenosis (the third 
universal tenet). The unbiased reader will consider it 
surprising that a,treatment modality that was tenta- 
tively incorporated into clinical practice marginally 
more than a decade past and is attended by a “recur- 
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rence rate” of 12% to 55% within 6 months (Fig. 1) 
is already widely accepted, especially because there is 
no hard evidence that longevity can be improved. 
(Only since 1987 have formal, randomized prospec- 
tive studies been initiated to compare PTCA and 
coronary artery bypass grafting [CABG] in terms 
of effect on long-term morbidity and mortality; 
thus objective results will not be available for some 
time.) 
Innovators and exponents of new treatment mo- 
dalities may allow their enthusiasm to compromise 
their objectivity, which probably explains why many 
interventionalists armed with the latest device ac- 
quire the expertise to use it largely through self- 
training techniques and assess its impact by clinical 
observations in the short term, allowing their judg- 
ment to be influenced more by anecdotal experience 
than by the results of carefully controlled prospective 
clinical studies. The value of all new treatment mo- 
dalities must be submitted to-objective and critical 
assessment through such studies by using the best 
available methodological analytical techniques. The 
advent of computer-assisted quantitative coronary 
angiography18-20 has demonstrated the fallibility of 
traditional visual and user-dependent techniques for 
assessment of the coronary cineangiogram,21 on which 
most of, if not all, the early reports on restenosis af- 
ter angioplasty are based. Tenets founded on the re- 
sults of early clinical studies must, therefore, be re- 
examined in the light of new revascularization and 
imaging technology, and we must be prepared to 
consider potential changes in basic philosophic and 
methodological approaches to both the treatment of 
coronary disease and evaluation of outcome after 
treatment as a consequence of fresh insights pro- 
vided. 
In the following paragraphs we review restenosis 
from the angiographic point of view because it is 
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Fig. 1. Nonscientific figure depicting restenosis rates from selection of published studies with different 
angiographic follow-up rates (57%-loo%), follow-up intervals (1-9 months), 11 different restenosis crite- 
ria, and various angiographic analysis techniques. 
Table I. Angiographic definitions of restenosis that have 
been used in various clinical studies. NHLBI 1,2,3, and 4 
are criteria for angiographic restenosis, as laid out by the 
National Heart, Lung, and Blood Institute of the United 
States 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
A diameter stenosis ~50% at follow-up.22 
An immediate post-PTCA diameter stenosis <50% 
that increases to 150% at follow-up.23,26 
As for 2, but a diameter stenosis 270% at follow-up 
(NHLBI 2).24 
Loss during follow-up of at least 50 510 of the initial gain 
at PTCA (NHLBI 4).25 
A return to within 10% of the pre-PTCA diameter 
stenosis (NHLBI 3).26 
Loss ~20% diameter stenosis from post-PTCA to fol- 
low-up.27 
Loss 230% diameter stenosis from post-PTCA to fol- 
low-up (NHLBI 1).23 
A diameter stenosis 270% at follow-up.28 
Area stenosis ~85% at follow-up.2g 
Loss 21 mm2 in stenosis area from post PTCA to fol- 
low-up.ss 
Loss ~0.72 mm in minimal luminal diameter from 
post-PTCA to follow-up.31 
Loss ~0.5 mm in minimal luminal diameter from 
post-PTCA to follow-up.32 
Diameter stenosis >50% at follow-up with >lO% de- 
terioration in diameter stenosis since PTCA of a previ- 
ously successfully dilated lesion (defined as diameter 
stenosis <50% with a gain of >lO% at PTCA).33 
through this medium that most research has been 
performed and angiography is still the only univer- 
sally used objective clinical tool for evaluation of im- 
mediate and long-term results of intervention. In this 
vein we briefly outline the main discrepancies in the 
restenosis literature and discuss the impact of quan- 
titative coronary angiographic studies on under- 
standing of the restenosis process. We describe some 
new conceptual approaches to the study of resteno- 
sis that we have developed through our own experi- 
ence in clinical studies, with serial computer-assisted 
quantitative coronary angiographic analysis (in pa- 
tients treated by balloon angioplasty, directional 
atherectomy, and stent implantation) and compare 
these approaches with findings of other groups. 
Through these new approaches we have attempted to 
bridge the gap from angiography to pathology and 
have explored the theoretic relationship between 
vessel wall injury at intervention and subsequent 
restenosis. The ultimate aim of this article is to pro- 
pose the use of the approach described here as a kind 
of unifying strategy to studying the restenosis phe- 
nomenon through coronary angiography to resolve 
the currently differing methods. 
RESTENOSIS: UNCERTAINTIES AND DISCREPANCIES 
IN DEFINITION CRITERIA 
The first step to improved understanding of the 
restenosis phenomenon is an accurate, meaningful, 
and universally accepted definition. Unfortunately,, 
at this time no such agreement exists, and there have 
been at least 13 different definitions based on coro- 
nary angiographic findings and applied by various 
clinical investigators attempting to address the prob-, 
lem of restenosis through clinical studies in recent 
years (Table I).22-33 Most of these are arbitrary cat- 
egoric cut-off points and, although some are based one 
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Fig. 2. Graphic representation of MLD and reference diameter (RD) values as reported in studies of 
Nobuyoshi et a1.32 and Serruys et al. 31 showing virtually identical time trends during 6-month follow-up. 
(From Serruys et al. J Intervent Cardiol 1991;4:265-76.) 
historical physiologic concepts,34 the measurement 
used is percent diameter stenosis, which is inherently 
flawed by the method of its computation, as we de- 
scribe later. Furthermore, a single cut-off point can- 
not accurately describe what is essentially a “moving 
target” (Fig. 2), as has been independently dem- 
onstrated almost simultaneously by our group3r 
and Nobuyoshi et al. 32 By using predetermined seri- 
al angiographic follow-up at 1, 2, 3, and 4 months 
(Nobuyoshi et al. carried out additional angiography 
at 6 and 12 months), both groups showed that some 
degree of renarrowing occurs in most dilated lesions 
and is a time-related phenomenon developing in the 
first 4 months after therapy and rarely progressing 
after 6 months. 
Percent diameter stenosis is traditionally calcu- 
lated by assuming a normal diameter value for a seg- 
ment of coronary vessel immediately proximal or 
distal to area of interest as a reference point. This 
assumption has been shown to be erroneous, partic- 
ularly in the context of multivessel disease, when 
there is virtually always diffuse intimal and/or sub- 
intimal thickening35> 36 and variable age-related or 
compensatory ectasia,37 and after interventions when 
the reference ‘diameter becomes involved in the res- 
tenosis process. 38-40 In recent years quantitative an- 
giographic studies have clearly and definitively re- 
vealed that labsolute luminal measurements such as 
minimal luminal diameter (MLD) or minimal cross- 
sectional area of coronary narrowings provide more 
reliable and meaningful information than percent 
diameter stenosis with regard to hemodynamic sig- 
nificance of an obstructive coronary lesion.41-45 
To circumvent the potential for inaccuracy with 
respect to percent diameter stenosis measurements 
calcmated by using an arbitrarily selected reference 
segment by the observer, the computer-based Car- 
diovascular Angiographic Analysis System (CAAS) 
(described further later) generates the interpolated 
reference diameter.20y 44, 45 The contour detection al- 
gorithm reconstructs how the arterial borders of the 
segment of interest should appear in the disease-free 
state by the technique of interpolation. According to 
this process, the actual lesion itself (obstructed 
region/segment) is excluded by using the curvature 
analysis, which detects the proximal and distal ends 
of the lesion (this process may be less accurate in dif- 
fusely diseased vessels than where there is a discrete 
stenosis). Then, in a continuous fashion, on the basis 
of the detected contours of the proximal and distal 
segments and allowing for anatomic vessel tapering, 
by using a second-degree polynomial function, the 
arterial contours over that segment are interpolated. 
The measurement taken as the reference diameter, 
then, is the interpolated reference diameter (from the 
so-called diameter function curve) at the site of the 
minimal luminal diameter (Fig. 3). The theoretic ba- 
sis of and actual mathematic steps involved in this 
process have been described in detail in technic.al 
publications in the past, and their intricacies are be- 
yond the scope of this article. 
Fig. 4 ,illustrates the potential, pitfalls of the arbi- 
trary selection of proximal and/or distal coronary 
segmente as a reference point and how a more objec- 
tive measurement of percent diameter stenosis can be 
derived by using the interpolated reference diameter. 
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Fig. 3. Graphic representation of CAAS measurement of interpolated reference diameter. Actual luminal 
contour is detected by edge detection technique. Proximal and distal extremities of obstructive lesion are 
determined from curvature analysis of detected contour; thus identified lesion is then excluded from de- 
termination of interpolated reference diameter. Second-degree polynomial function is applied to diametric 
measurements made from each scan line (every 0.1 mm) of segment proximal and distal to lesion; anatomic 
vessel tapering is taken into consideration and vessel contours in area of lesion are reconstructed and in- 
terpolated into diameter function curve (shown as dashed line in analysis and corresponding upper and 
lower vessel contours). Actual interpolated reference diameter used then is diametric measurement, from 
diameter function curve, at point of minimal luminal diameter, as shown. 
What is the 
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Fig. 4. Variability in percent diameter stenosis measurements of same lesion as a result of arbitrary 
selection of reference diameter by “user,” and more objective derivation of percent diameter stenosis by 
user-independent method of interpolated reference diameter (IRD). For stenosis where minimal luminal 
diameter is measured at 0.8 mm, if user-defined proximal or distal reference segment or mean of both is 
selected then resultant measure of percent diameter stenosis for obstructing lesion is 75 % , 77 % , or 76 % , 
respectively. I f  computer-determined interpolated reference diameter (shown asupper and lower thick dark 
lines) is used, diameter stenosis measurement of 66% is obtained. Prox ref diam, Proximal reference di- 
ameter; dist, distal; %DSten, percent diameter stenosis. (From Serruys P, et al. J Intervent Cardiol 
1991;4:265-76.) 
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Fig. 5. A, Cumulative incidence of restenosis during 5-month (MTHS) follow-up period as defined by three 
different criteria among 490 successfully dilated lesions. NHLBI 4, Criterion 4 of National Heart, Lung and 
Blood Institute of America: loss of >50% of initial gain at angioplasty; 250%) ~50% diameter stenosis 
(OS) at follow-up; ~0.72 mm = 20.72 mm loss in minimal luminal diameter from after angioplasty to fol- 
low-up. (From Beatt et al. J Am Co11 Cardiol 1990;15:491-8.) B, Venn diagram showing distribution of le- 
sions fulfilling the different criteria applied in Fig. 3. Note that, of 153 lesions undergoing restenosis ac- 
cording to at least 1 of 3 criteria applied, only 43 fulfill all 3. It is appreciated how different definitions of 
restenosis define separate populations. (From Beatt et al. J Am Co11 Cardiol 1990;15:491-8.) 
Nevertheless, even with use of interpolated reference 
diameter, inaccuracy introduced by the presence of 
diffuse arterial disease (and by the effect of interven- 
tion) is not surmounted, and the use of minimal lu- 
minal diameter appears more reliable for the purpose 
of important clinical research, as will be elaborated 
further in later sections of this article. 
As a consequence of definition inaccuracy, in addi- 
tion to variable angiographic follow-up rates (57 % to 
100 % ) and the continued use of visual assessment of 
the coronary angiogram by most investigators, the 
reported incidence of restenosis varies widely (Fig. 1). 
Applying three different and widely used definitions 
to a series of 398 lesions serially measured during 
6-month follow-up, our group3r demonstrated that: 
(1) the greatest single determinant of the restenosis 
1248 Sei-ruys et al. 
November 1993 
American Heart Journal 
rate is the choice of definition (Fig. 5, A), and (2) even 
if the eventual incidence of restenosis is similar, dif- 
ferent definitions identify different patient popula- 
tions (Fig. 5, B), making risk factor determination 
(and indeed meaningful study of the natural history 
of the restenosis process) impossible.46 These diver- 
sities are almost certainly responsible for much of the 
confusion surrounding the concept of restenosis after 
PTCA. 
WHAT IS RESTENOSIS? 
Restenosis refers to the combined biologic (throm- 
bo-rheo-fibro-proliferative) healing processes taking 
place after the mechanical or physicai injury im- 
parted by balloon inflation or other percutaneous 
device, which ultimately lead to a progressive renar- 
rowing of the patent lumen to a greater or lesser de- 
gree during the immediate weeks and months after 
the therapeutic procedure. This process of response 
to injury has been most extensively studied in the 
context of balloon dilatation and, as such, appears to 
loosely consist of four elements: (1) Elastic recoil, a 
natural property of intact blood vessels to respond to 
stretch. This phenomenon has been characterized by 
quantitative angiography47-50 and by intravascular 
ultrasound (IVUS)51; although available data are 
somewhat conflicting, on balance elastic recoil is de- 
picted as occurring immediately after balloon defla- 
tion 47, 4g with no significant further recoil during the 
succeeding 24 hours52a 53 and thus has a doubtful real 
contribution to the process of late luminal renarrow- 
ing4gJ 54, 52; (2) subintimal platelet deposition, mural 
thrombus formation, and consequent organization 
may result in rapid luminal obstruction or early res- 
tenosis56 after the apparently unavoidable intimal 
disruption induced by balloon dilation@; further- 
more, these early “hemorrheological responses” to 
vessel wall injury57 are likely to be an initial pathway 
to (3) fibrocellular neointimal hyperplasia, which is 
widely regarded as the final pathologic process by 
which progressive luminal renarrowing develops in 
the months after PTCA1> 58-62; and (4) reaccumula- 
tion or acceleration-progression of classic atheroscle- 
rotic plaque.@ 
Alternative pathologic partidigms. The conventional 
assumption of an outgrowth of proliferating cells 
(presumably smooth-muscle cells) from the dam- 
aged vessel media to form the neointimal has lately 
been challenged by Schwartz et al.63 On the ba- 
sis of extensive experience with a domestic swine 
mode1,64$65 they assign a, central role to mural 
thrombus formation at the site of injury, which has 
already previously been well recognized as a key 
event.l> 55, 57-5g~ 61, w  67 From this point in the para- 
digm a new aspect is introduced whereby the fresh 
mural thrombus becomes rapidly endothelialized (3 
to 4 days after injury) and is then infiltrated by 
mononuclear cells from the luminal surface inward. 
The degenerating thrombus is subsequently colo- 
nized by proliferating ol-actin staining cells (becom- 
ing visible from day 6 onwards) whose origin and ex- 
act nature remains elusive (although they are possi- 
bly smooth muscle cells or myofibroblasts), again 
from the luminal surface inward (in the opposite di- 
rection to that which is hypothesized in the current 
conventional model), with concomitant production 
of extracellular matrix, eventual complete resorption 
of the thrombus, and the ultimate formation of ma- 
ture neointima. 
Karas et a1.68 have also presented a model of res- 
tenosis by using balloon dilatation or implantation of 
a balloon-expandable stent in normolipemic domes- 
tic swine. They observed marked intimal smooth- 
muscle cell proliferation and an increase in extracel- 
lular matrix, destruction of the internal elastica, and 
thinning of the arterial medial layer, both in stented 
and balloon-dilated segments. Intimal proliferation 
was more prominent and significantly greater in 
stented segments by morphometric analysis; in addi- 
tion, residual luminal area was significantly less in 
these segments. These histopathologic changes were 
described as being comparable with those observed in 
human restenosis. Furthermore, reactive inflamma- 
tory infiltrates were frequently observed in proxim- 
ity to the stent filaments, suggesting a foreign body 
type of reaction. The authors hypothesize that, 
despite provoking more intimal proliferation, stent- 
ing maintains a greater morphometric luminal area 
than balloon dilatation through the achievement of a 
larger lumen by continued mechanical opposition of 
elastic recoil. These findings present circumstantial 
evidence that agrees with the description of a pro- 
portional relationship between the extent of neo- 
intimal hyperplasia and the severity of vessel wall 
injury by Schwartz et al. 65 However, the authors dis- 
agree with the hypothesis of Schwartz et al.63 regard- 
ing the central role of thrombus in the process of res- 
tenosis, on the basis of the rarity of angiographic ev- 
idence of large space-occupying clots in clinical 
practice, and suggest that excessive arterial injury 
was induced in their model, thus limiting its use as a 
screening tool. 
Further observations of coronary artery dilatation 
in the porcine overstretch model without stenting 
provided no evidence for a space-occupying throm- 
bus6g as suggested by Schwartz et al.65 Serial exam- 
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ination of the dilated arteries at 1,3,7,14, and 28 days 
showed little or no thrombus but active migration 
and proliferation of cells from the area of the dis- 
rupted media. Examination of these healed lesions 
and similar lesions from patients70 failed to reveal the 
footprints of preexisting thrombus, that is, hemo- 
siderin deposits, etc. These divergent findings may 
primarily relate to the extensive use of stents in the 
MayoClinicmodel (whichuniformlyproduces throm- 
bus) and the overstretch without stenting used in the 
Emory model (which was found not to produce sig- 
nificant thrombus). 
Intracoronary fiberoptic angioscopy allows safe 
and rapid assessment of the site of percutaneous in- 
tervention.56 One recent clinical study small and 
preliminary, reports the presence of luminal throm- 
bus in two thirds of patients immediately after 
angiographically successful balloon dilatation, with 
progression in thrombus volume, within 1 hour, in 
half of these, while contrast angiography failed to 
provide clear evidence of intraluminal thrombus.71 
Further recent technologic advances in angioscopic 
hardware will undoubtedly facilitate even more de- 
tailed and “microscopic” evaluation of the coronary 
lumen in clinical studies.72 Thus the technology now 
appears to be available to prospectively study the role 
of intraluminal thrombus in the restenosis process 
and in the clinical setting, and such studies may al- 
ready be underway in some institutions. 
Whatever the exact nature of the histopathologic 
process, it is evident that the corresponding angio- 
graphic appearance of progressive luminal renarrow- 
ing is not well encapsulated by traditional conven- 
tional definitions or criteria such as “loss of greater 
than 50 % of the gain” or “greater than 50 % diame- 
ter stenosis at follow-up,” two of the most widely used 
definitions in daily clinical practice, and in resteno- 
sis prevention studies (Table I) and trials of new de- 
vices. Schwartz et al.65 and Beatt et a1.73 have each 
highlighted this inherent limitation of conventional 
restenosis criteria and the consequent potential for 
misinterpretation of results of clinical trials relying 
on such criteria. Similarly, Karas et al.68 also draw 
attention to the possibility of considerable intimal 
proliferation without angiographic restenosis. 
Because current understanding of the restenosis 
process is at best fragmented, until our knowledge 
becomes more complete, it is crucial to make sensi- 
ble use of the most objective descriptive methodolog- 
ical approaches available, especially in the minefield 
of clinical research. The question is, what are the 
most objective, reliable, and reproducible methods of 
assessing restenosis? 
ASSESSMENT OF RESTENOSIS: SYMPTOMS, 
FUNCTION, FLOW, OR LUMEN? 
Coronary obstructions, whether of primary ather- 
omatous origin or arising as a response to the con- 
trolled mechanical or thermal injury inherent in the 
various currently available nonsurgical therapeutic 
coronary interventions, can be described from a 
number of different viewpoints: (1) by the symptom- 
atic sequelae. Although improvement in quality of 
life (and life expectancy) is the goal of any therapeu- 
tic modality, it is also the least objective yardstick by 
which to evaluate the impact of treatment.74> 75 
(2) By the physiologic disturbance in myocardial 
perfusion caused. The physiologic effect of a coronary 
stenosis may be most certainly the ultimate determi- 
nant of management for the individual patient. The 
increasing battery of noninvasive investigations avail- 
able for this purpose contribute vital information 
necessary for clinical decision making, but they can- 
not provide the reproducibility and objectivity77-7g 
required to assess the process of luminal renarrowing 
after percutaneous revascularization in large patient 
groups in the context of clinical trials. In daily clin- 
ical practice it may be considered most prudent to 
regard restenosis according to the need for a repeat 
revascularization procedure; thus it is important for 
the reader to recognize that this treatise is primarily 
focused on the evaluation of outcome after interven- 
tions in the context of large clinical trials of new de- 
vices or therapeutic approaches rather than as a di- 
rect guide to general clinical practice. Nevertheless, 
it must not be forgotten that conclusions drawn from 
the outcome of such trials provide us with the type of 
information that is ultimately instrumental in our 
daily clinical decision making, hence the paramount 
importance of design, method, and approach in these 
trials and studies. 
(3) By its hemodynamic consequences, that is, re- 
duction in coronary blood flow caused by the ob- 
struction. Regional coronary flow reserve (CFR) (de- 
fined as the ratio of maximal to resting coronary 
blood flow) may be directly measured at cardiac 
catheterization by a number of different techniques, 
or alternatively may be derived from values obtained 
by quantitative angiography.42 Absolute coronary 
blood flow itself can be measured by Doppler wire, 
and transstenotic pressure gradients may be ob- 
tained by using ultra-thin fiberoptic or fluid-filled 
catheters. Further sophisticated and precise hemo- 
dynamic measurements can be obtained during car- 
diac catheterization. However, these are mainly re- 
search tools that are not at this time generally avail- 
able to the general nonacademic interventionist and 
1,250 Serruys et al. 
November1993 
American Heart Journal 
are unapplicable for m’ulticenter clinical studies in 
large patient populations. 
(4) By its anatomic configuration, namely degree 
of luminal narrowing. For the present, this aspect is 
best assessed by conventional contrast angiographic 
techniques, although intravascular ultrasound 
(IVUS) is emerging as an exciting and promising im- 
aging modality3s 51~ s5 and will undoubtedly have a 
useful application in the future in this area. As yet, 
IVUS is in the developmental stage and many tech- 
nical obstacles need to be surmounted, particularly 
transducer size (models used in the most recently 
published studies are 1.83 mm in diameter, although 
a 1.15 mm prototype is being tested,36 cost, ethical 
considerations, and objective delineation of the rela- 
tionship between IVUS images and actual morphol- 
ogy of the blood vessel wa1Jg5 before it can be consid- 
ered as a realistic or practical alternative to carefully 
controlled angiography. 
At this time the coronary cineangiogram is still the 
only universally available imaging modality for ex- 
amination of coronary anatomy; quantitative angio- 
graphic techniques as described later have emerged 
as the gold standard for the accurate and objective 
analysis and description of the basic cineangiogram, 
particularly in the context of large, multicenter res- 
tenosis prevention clinical studies and trials of per- 
cutaneous coronary revascularization devices. 
Coronary luminal measurement by quantitative coro- 
nary angiography: The CAAS approach. Quantitative 
coronary angiography (QCA) has been used at our 
institution for a decade” and is becoming increas- 
ing available with the development of on-line quan- 
titative angiographic computer software for digi- 
tal cineangiographic imaging (DCI) equipment 
in the catheterization laboratory. The CAAS 
system has been rigorously and extensively vali- 
dated, and the methodology is described in detail 
elsewhere.1s-20~ 87s 88g g5-g7 To explain the method 
briefly: After a selected cineangiographic image has 
been converted to an optically magnified digital im- 
age (digitization; this step may soon be rendered un- 
necessary by the rapid development of on-line digi- 
tal systems), the contours of the selected coronary 
segment are detected automatically (so called con- 
tour or edge detection) by the computer algorithm 
applied to the brightness profile of the segment along 
scan lines that are perpendicular to the segment cen- 
terline (scan lines are made every 0.1 mm the 
approximate size of 1 pixel). The centerline is deter- 
mined by the computer, which uses as starting points 
*18-20,31,38,42-48,86-108,111,112,115-120,127,135,136. 
a series of arbitrary centerpoints selected by the an- 
alyst, but for which the algorithm can retroactively 
correct and regenerate the true centerline of the seg- 
ment image. Absolute diameter measurements are 
determined in millimeters by using the outer border 
of the. contrast-free angiographic catheterg5 (the dis- 
tal 20 cm of each individual catheter used for contrast 
injection is retained and measured by micrometer) as 
a scaling or calibration device. A correction factor is 
then introduced for the so-called pincushion distor- 
tion introduced by the image intensifier (there are 
557 different pincushion correction factors in the 
CAAS database relating to all the catheterization 
laboratories from which we receive cinefilms for 
analysis). Pincushion distortion is minimal with 
modern angiographic systems, and this step may not 
be necessary in the coming years. The interpolated 
reference diameter is obtained as previously out- 
lined. From the absolute measurements (minimal lu- 
minal diameter, maximal luminal diameter, mean 
luminal diameter, and lesion length) and the inter- 
polated measurements obtained by the computer 
(symmetry, curvature, inflow-outflow angle, plaque 
area, roughness), many others may be derived, such 
as percent diameter stenosis, percent area stenosis, 
theoretic transstenotic pressure gradient, calculated 
Poiseuille resistance, and calculated turbulence re- 
sistance. 
Videodensitometry assesses the area of a stenosis 
by comparing the density of contrast in the diseased 
and normal segment, which has the advantage that 
only a single angiographic projection is required. 
However, this must be perfectly perpendicular to the 
long axis of the vessel, and there must be no overlap- 
ping or closely parallel sidebranches or other dis- 
turbing radiopacque structures. Only relative values 
are provided so data obtained by contour detection 
are also necessary to provide absolute measurements. 
A further drawback of this otherwise promising 
technique is its high sensitivity (it is even more sen- 
sitive than contour detection) to x-ray scatter, veiling 
glare, beam hardening, and suboptimal contrast fill- 
ing of the vessels. These basic limitations have 
deterred the application of the technique to impor- 
tant clinical angiographic studies. In the latest up- 
dated CAAS system, however, steps have been taken 
to .overcome these drawbacks; results of validation 
studies are eagerly awaited. 
Minimal luminal diameter. Of all the measurements 
acquired by quantitative angiography, the absolute 
value of the minimal luminal diameter (MLD) has 
been shown to be the greatest single determinant of 
the hemodynamic consequences of a stenosis because 
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this parameter affects blood flow by a fourth power 
term.42T 8o, 84y log It is therefore the most unambigu- 
ous, objective, and reproducible parameter to use for 
primary measurement of coronary arterial (or bypass 
graft) luminal caliber and changes therein resulting 
from interventions, that is, the angiographic gain in 
minimal luminal diameter after intervention and 
subsequent loss during follow-up and, as described 
later, the proportional angiographic gain and loss (so 
called relative gain and relative loss which normalize 
the gain and loss for the actual vessel size. 
Criteria for definition of restenosis on the basis of 
change, in minimal luminat diameter during follow-up. 
Important multicenter trials examining the impact of 
various treatment strategies on restenosis have in re- 
cent years been availing of central, standardized, 
blinded, computer-assisted, quantitative angio- 
graphic analysis in angiographic core laborato- 
riesg8g gg, no-l14 and have begun to use the minimal 
luminal diameter (MLD) as the most objective and 
useful measurement.l15 In the past, our group used 
the long-term minimal luminal diameter measure- 
ment variability of the CAAS system as a means of 
identifying lesions undergoing significant or detect- 
able luminal change during follow-up after balloon 
angioplasty. 88 The SD of the mean difference be- 
tween MLD measurements of the same lesions at 
different points in time where no intervention was 
carried out was measured under a worst-case scenario 
and found to be 0.36 mm. Two SDS would identify 
with 95% confidence lesions undergoing a real, de- 
tectable, or significant change. By using the long- 
term lesion measurement variability it was believed 
might present an objective approach to dividing pa- 
tients monitored after PTCA into restenosis and 
nonrestenosis. 
That study may now be considered somewhat ob- 
solete because, as highlighted by Ellis and Muller,l16 
and as we ourselves had already recognized, a large 
number of limitations to this deffinition of restenosis 
are now evident. First, the developmental study used 
vessels with an average reference diameter of 3.7 
mm,88 whereas in two recent large multicenter rest- 
enosis prevention studies the mean reference diam- 
eter of treated vessels was 2.6 rnrn.llly 112 Further- 
more, the initial study used a worst case scenario 
whereas extensive standardization measures (use of 
intracoronary nitrates to control vasomotor tone, 
performance of angiography in exactly matched mul- 
tiple projections, careful identification and selection 
of an end-diastolic tine frame for QCA analysis, etc.) 
are now carried out in modern multicenter studies 
and furthermore post-PTCA measurement variabil- 
ity cannot be inferred from the original study because 
no intervention was carried out. 
We have completed a pilot study53 that provides 
clear angiographic data in this regard, whereby 
among 110 lesions (mean vessel size of 2.67 mm) 
studied after balloon angioplasty and at 24 hours 
(under optimally standardized conditions, i.e., 
matched angiographic projections, intracoronary ni- 
trate before angiography, full therapeutic anticoagu- 
lation) there was no difference in MLD (0.007 mm, 
p = 0.79), and the SD of the mean difference was 0.2 
mm. By extrapolation from these data, it can be con- 
cluded that the post-PTCA lesion measurement 
variability of the CAAS system is 0.2 mm; thus a 
change of 0.4 mm in MLD can be considered with 
95 % confidence to represent a real change and thus 
can be considered a potential criterion for detection 
of significant luminal loss or renarrowing. In the light 
of the well-recognized difficulties of angiographic in- 
terpretation of the postballoon angioplasty result, we 
believe this measurement variability to be eminently 
acceptable. 
It must be noted that the criterion we propose for 
detecting significant change in MLD over a period of 
time is the measurement variability of the analytic 
system being used and not 0.4 mm per se, because this 
is the variability of the CAAS system and may not be 
relevant to other systems. Ultimately, as alluded to 
already and as discussed further later in this article, 
the application of dichotomous criteria to the de- 
scription of long-term outcome after intervention is 
fraught with imprecision, conflict, controversy, and 
dissension. 
NEW INSIGHT TO THE RESTENOSIS PROCESS 
FAClLlTATED BY QCA 
Gaussian distribution. Although most biologic phe- 
nomena are distributed in nature in normal or gaus- 
sian fashion, the outcome of percutaneous coronary 
interventions and of pharmacologic restenosis pre- 
vention trials have been traditionally assessed up to 
now by using categoric cut-off criteria for the occur- 
rence (or not) of restenosis because, as previously 
mentioned, clinical decision making is ultimately a 
binary process. However, for the purposes of large 
multicenter controlled clinical trials, estimation of 
sample size required to demonstrate the statistical 
significance of a treatment effect has been based on 
the assumption of a gaussian distribution for the loss 
in MLD during follow-up after balloon angioplasty.l18 
That this discussion is not merely a matter of 
semantics is illustrated in the example shown in Fig. 
6.118 A significant beneficial treatment effect is de- 
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Fig. 6. Gaussian model of restenosis in reference and treatment groups. Lower curve represents 30 % re- 
duction in minimal luminal diameter change at follow-up (-0.25 mm vs -0.40 mm) in treated group, upper 
curve denotes distribution of change in minimal luminal diameter (AMLD) found at follow-up in prospec- 
tive study at our institution. 31 If change of 0.72 mm is taken as cut-off point for restenosis, this categoric 
model would require 620 patients per group to have power of 90 % . (From Serruys PW et al. Interventional 
cardiology. Stuttgart: Hogrefe and Huber, 1990.) 
fined as a reduction in the mean loss in minimal lu- 
minal diameter during follow-up after balloon angi- 
oplasty by 30 % , that is, from 0.40 mm to 0.25 mm. It 
can be calculated that, assuming normal distribu- 
tions for the loss in MLD, 233 patients are required 
in each treatment group to demonstrate the signifi- 
cance of this difference at the 95% confidence level 
with a power of 90 % . If a categoric approach (rest- 
enosis yes/no) is used (applying loss in MLD of 10.72 
mm as the criterion of detectable significant loss), 
then the 0.15 mm difference in MLD is equivalent to 
a reduction in the restenosis rate from 25 % to 17.5 % ; 
to demonstrate that this difference is significant, 620 
patients will be required in each group, almost three 
times as many as required if a continuous ‘approach 
is applied. 
Historically, in a number of clinical studies focus- 
ing on various aspects of the restenosis problem Be- 
att et a1.s8> lig-r2i demonstrated that quantitatively 
measured changes in MLD and in reference diame- 
ter during the months after PTCA are normally dis- 
tributed.’ This view of a continuous unimodal distri- 
bution for luminal change after balloon angioplasty, 
although strongly challenged at that time, became 
the nidus of our philosophy regarding methodologi- 
cal approach to addressing the problem of resteno- 
sis.* The Beth Israel group subsequently strongly 
*47,48, 54, 73, 94, 100-108, 111, 112, 118. 
corroborated these early reports, demonstrating sim- 
ilar distribution patterns of luminal change after in- 
tervention in patients undergoing directional athe- 
rectomy and stent implantation.122s 124 
At a later date, however, the Emory group exam- 
ined, by clinical estimation of percent diameter 
stenosis, a large cohort of patients undergoing bal- 
loon angioplasty and follow-up angiography. They 
found a bimodal distribution and concluded that 
there was either a physiologic bimodal distribution or 
a systematic measurement error around the 50% 
diameter stenosis mark when clinically evaluating 
cineangiograms. lz5 This finding, if confirmed, would 
therefore justify a categoric approach to the assess- 
ment of angiographic outcome in clinical trials, 
thereby challenging the emerging assumptions of a 
continuous distribution arising from the separate 
findings of our group and the Beth Israel group. This 
prompted our group to reinvestigate this phenome- 
non in a much larger patient ,population than had 
been studied in the original studies,“8p iLg-r2i and un- 
der more standardized and ,&onsistent quantitative 
angiographic conditions. In this study of 1234 #pa- 
tients it was demonstrated unequivocally that lumi- 
nal renarrowing after PTCA, whether assessed by 
using minimal luminal diameter or percent diameter 
stenosis at follow-up or the change in these measure- 
ments during follow-up, clearly follows a gaussian or 
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Fig. 7. Histogram of change in minimal luminal diameter during 6-month (MTHS) follow-up (F-UP) of 
1445 primary lesions treated by coronary balloon angioplasty during two large restenosis prevention trials. 
Theoretic gaussian curve, given mean and SD, is superimposed, clearly illustrating that luminal renarrow- 
ing is normally distributed phenomenon. (From Rensing et al. J Am Co11 Cardiol 1992;19:939-45.) 
normal distribution (Fig. 7g4) in agreement with our 
own earlier findings,389 73 and the reports by Kuntz et 
a1.124 in patients treated by other devices. These cor- 
roboratory findings appear to identify a basic flaw in 
the clinical impression of a bimodal phenomenon. On 
this basis, it is our contention that a dichotomous 
view of restenosis is inappropriate and that categor- 
ically generated restenosis rates should no longer be 
the main focus of important scientific studies or dis- 
course in this vital area. 
There may be sound clinical reasons for selecting 
particular angiograpbic definitions of restenosis, but 
in the context of scientific studies or restenosis pre- 
vention trials, the use of a blanket, categoric cut-off 
point (e.g., X0% diameter stenosis) conveys no 
measure of the extent of luminal renarrowing and 
therefore cannot provide a comprehensive assess- 
ment of the effect of a particular therapeutic ap- 
proach for the control of the biologic process of res- 
tenosis. Furthermore, because the threshold level for 
absolute (or relative) luminal renarrowing that is 
physiologically or clinically significant is unknown, it 
is much more realistic and meaningful (and requires 
much fewer patientsI”) to study the overall effects of 
an intervention in terms of the mean change in min- 
imal luminal diameter for the entire group.rlrp r12 We 
believe, furthermore, that results of intervention tri- 
als may be simply presented in graphic form by us- 
ing cumulative distribution curves displaying change 
in MLD during follow-up for treated versus placebo 
populations (Fig. 8)l11p 1121 24 or indeed for PTCA 
versus stent or atherectomy13, lo47 lo6 as discussed 
later. 
Potential pitfalls of angiographic studies. Having laid 
out this scheme of the angiographic representation of 
the phenomenon of restenosis, it must be taken into 
consideration that the entire hypothesis of a Gaus- 
sian phenomenon hinges more or less on the accuracy 
and reproducibility of quantitative angiographic 
measurements. Although it seems clear from the 
foregoing evidence that luminal renarrowing or res- 
tenosis after interventions is a continuous or nor- 
mally distributed phenomenon, it must be recognized 
that our observations do not always give a clear view 
of reality. The measurement approaches used to 
quantify coronary luminal dimensions ‘from cinean- 
giograms have inherent associated measnrement vari- 
ability that may be attributed to a large number of 
causes. The importance of knowing this measure- 
ment variability for the purposes: of comparing the 
results of studies carried out by using different mea- 
surement systems is self-evident. It could be hypoth- 
esized that this measurement variability may be 
clouding our view of reality. 
To demonstrate this point, let us construct a 
hypothetical scenario whereby restenosis is in reality 
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Fig. 8. Cumulative frequency (distribution) curves of change in minimal luminal diameter from after an- 
gioplasty to follow-up (F-UP) in control and treatment groups for CARPORT restenosis prevention trial 
showing no treatment benefit. CUM%. Cumulative percentage of patients. (From Serruys et al. Circula- 
tion 1991;84:1568-81.) 
a discrete disease process, so that by using a perfectly 
accurate and precise quantitative angiographic mea- 
surement system and plotting the change in minimal 
luminal diameter in a frequency distribution plot two 
groups of patients could be delineated, one in which 
restenosis occurred and the other in which no rest- 
enosis developed (Fig. 9). In panel A, the no resteno- 
sis group is denoted by the curve n, a relatively nar- 
row gaussian function showing no overall loss in MLD 
(mean = 0, SD = 0.2 mm). The restenosis subgroup 
response curve r was also taken to be Gaussian but 
broader (more variable) than the normal response, 
and it displayed a significant loss in MLD (mean = 0.5 
mm, SD = 0.4 mm). The difference in the assumed 
variability of these groups merits an explanation. In 
the no restenosis group the variability in the mea- 
sured loss in MLD was assumed to stem from uncon- 
trollable changes in lesion tone between the post- 
PTCA and follow-up angiograms. Such variance was 
also assumed for the lesions undergoing restenosis 
but, in addition, the process of restenosis was also 
assumed to be variable, thereby exaggerating the 
variability in loss of MLD in this group. When the 
subgroup responses are added, the combined study 
population is seen to be unimodal but skewed toward 
the right as demonstrated by the heavy solid curve 
(panel A). This population response (the actual 
response) must now be measured by a QCA system to 
form our observations. This system, however, is not 
perfect because frame selection and computer-as- 
sisted image interpretation may not be exactly accu- 
rate and reproducible. To account for such measure- 
ment problems, panel B shows two solid gaussian 
curves which were used to represent the statistical 
characteristics of two QCA measurement systems. 
Curve h denotes a highly precise and accurate system 
(mean difference between repeated measurements of 
MLD = 0 mm, SD of the mean difference = 0.1 mm); 
curve m is a medium-precision but highly accurate 
system (mean difference = 0 mm, SD = 0.3 mm). 
Measuring MLD loss by these systems is akin to 
mathematically convolving the study population in A 
with a measurement characteristic from B, the re- 
sults of which are shown in panels C and D. In panel 
C the combined population response (solid curve in 
A) has been measured with the high-precision QCA 
system, resulting in observations that closely mirror 
the true population response. Panel D shows the ob- 
servations (solid heavy curve) resulting from less 
precise measurement of the study population by 
means of the medium-precision QCA measurement 
system. The measurement process has blurred our 
observations to the point that the measured loss in 
MLD now approaches a gaussian distribution (the 
light-dashed line inD), which has the same mean, SD, 
and number of observations. 
The above scenario proposes an alternative expla- 
nation for the observed gaussian distribution of COT- 
onary luminal measurements at.follow-up after cq- 
onary interventions and the change in dimensiorjs 
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Fig. 9. Simulated PTCA restenosis study. A, solid curve represents entire study population composed of 
two separate but overlapping subgroups, both of which can be described by gaussian function. Curve n de- 
scribes loss in MLD for 1000 lesions that did not restenose (mean loss = 0 mm, SD = 0.2 mm). Curve r, loss 
among 500 lesions that did undergo restenosis (mean loss = 0.5 mm, SD = 0.4 mm). B, Measurement char- 
acteristics of two separate QCA systems, high accuracy and precision system (curve h, with accuracy of 0 
mm and precision of 0.1 mm) and high accuracy but medium precision system (cut-w m, with accuracy = 0 
mm, precision = 0.3 mm). Heavy curves in C and D display distributions of observations that would be 
produced by measuring actual loss in MLD in populations of lesions in A by high-precision system (C) and 
medium precision system (P) by using simulation process called curve convolving. Dashed curves in panels 
C and D show corresponding gaussian distributions. 
during follow-up (as reported by our group38, 73s g4y 121 
and by the Beth Israel group,lz2p 124) namely impre- 
cise measurements of a mixed population of lesion 
responses to intervention. However, without further 
objective investigation this proposal has no more va- 
lidity than any other reasonable hypothesis that fits 
the observations. 
The point is that it is important be careful in what 
is concluded or excluded based on observations. Ac- 
cepting that there may be multiple explanations for 
a given set of observations, is there anything that can 
be done to sharpen our view of reality? We should 
make all reasonable efforts to minimize measurement 
inaccuracy and imprecision. As shown in our exam- 
ple, even an imprecision of aO.3 mm in measuring 
MLD loss may significantly contort the observations 
and thus confound the conclusions drawn. Although 
this simulation featured QCA measurements as study 
endpoints, the principles are applicable to all chosen 
endpoints. If, for example, clinical endpoints were 
used to evaluate restenosis, we can only wonder how 
blurred the observations might be as a result of inac- 
cura.te or imprecise assignments of clinical events to 
lesion restenosis. Additionally, sensitive and flexible 
analyses of the observed data need to be explored. In 
this regard it might be worthwhile to use our knowl- 
edge of the measurement process to try to unblur our 
observations. Deconvolution, curve-fitting, and 
curve-stripping procedures are often used in signal 
and image processing to remove known artifacts, re- 
duce noise, and separate overlapping phenomena. It 
may prove interesting to see whether such methods 
could be applied usefully in analysis of restenosis 
trials. 
Clinical correlations of measured MLD. Danchin et 
al.126 demonstrated a correlation between the thresh- 
old to exercise-induced myocardial ischemia (as dem- 
onstrated by thallium-201 tomoscintigraphy) and an 
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Fig. 10. A, Percentage correct classification of recurrence of angina (sensitivity) and absence of angina 
(specificity) as function of absolute value obtained for MLD by QCA at follow-up after PTCA in 350 pa- 
tients taking part in restenosis prevention trial. lrl Intersection of two curves represents cut-off point with 
greatest diagnostic accuracy. (From Rensing BJ et al. J Am Co11 Cardiol 1993;21:317-24.) B, Percentage 
correct classification of a’positive exercise test result (horizontal or down-sloping ST-segment depression . 
of >1 mm measured by callipers 80 msec after the J-point) and negative exercise test result (specificity) 
as function of absolute value obtained for MLD by QCA at follow-up in same patient population as for Fig. 
IO, A. Intersection of two curves represents cut-off point with greatest diagnostic accuracy. 
absolute value for minimal luminal diameter from 
which they conclude that an MLD r2 mm is suffi- 
cient to provide freedom from myocardial ischemia in 
95% patients. Furthermore, Rensing et al.lu have 
reported that in 350 patients who underwent suc- 
cessful PTCA for single-vessel disease (as part of a 
large prospective multicenter restenosis prevention 
trial) and had exercise testing and repeat coronary 
angiography at follow-up an MLD of 1.45 mm corre- 
lates with the threshold for recurrence of angina pec- 
toris (sensitivity and specificity: 72%).127 Exercise- 
induced ST-segment change was found to be a less 
reliable predictor of luminal renarrowing, although 
the point of greatest diagnostic accuracy for a posi- 
tive exercise test corresponded with a measured 
MLD of 1.46 mm (Fig. 10). This information is 
somewhat surprising because it would be expected 
that a large number of additional variables should 
influence the relationship between minimal luminal 
diameter and exercise-induced angina or ST-seg- 
ment depression such as vessel size, extent of myo- 
cardium supplied, viability of myocardial tissue, 
presence of collateral circulation; use of antianginal 
medication, etc. When vessel size was taken into ac- 
count by dividing the study group in half according 
to the median v&se1 size,. the point of intersectionof 
the sensitivity and specificity curves were again vir- 
tually identical for recurrence of angina and a posi- 
tive exercise test, at 1.38 mm in vessels <2.63 mm and 
1.58 mm in vessels >2.63 mm in diameter. Thus it is 
clear that the vessel size does influence the minimal 
luminal diameter threshold for recurrence of angina 
or exercise-inducible ischemia. Nevertheless, the ob- 
servations suggest that the absolute value for MLD 
at follow-up may ultimately prove to be a simple and 
clinically useful parameter both for scientific studies 
and practical clinical patient management, a claim 
that deserves further and more objective evaluation. 
This implication supports the approach used in 
reporting two recent European multicenter resteno- 
sis prevention trialslrr> lr2 and that employed by 
other groups who have consistently focussed on the 
MLD at follow up in reporting on angiographic out- 
come, in patients treated by DCA and stent implan- 
tation 122-124,12%131 
As a measure of the extent of the hyperplastic 
healing process itself, the change in MLD during fol- 
low-up is clearly the parameter of-choice. Rensing et 
al.rz7 also investigated the clinical value of measured 
change in MLD during follow-up in predicting the 
physiologic significance of treated lesions 6 months 
after sucdessful balloon angioplasty and:fou.nd it to 
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be only slightly less accurate than absolute MLD at sonably be used. There are three basic principles: (1) 
follow-up, a deterioration of >0.30 mm yielding sen- the angiographic dimensions of the matched lesions 
sitivity and specificity of almost 70% for prediction are assumed to be identical; (2) the observed differ- 
of recurrence of angina and almost 60 % for a positive ence between the two identical lesions must be within 
exercise test result. Corresponding values for per- range of reproducibility of the computer analysis 
centage diameter stenosis measurements are pro- system being used (for the CAAS system this is +- 0.1 
vided in this study for comparative purposes for the mm, i.e., 1 SD of the difference between repeated 
benefit of clinicians; however, for the extensive rea- measurements of the same angiogram); and (3) the 
sons given earlier in this article we discourage the use reference diameter of the vessels to be matched are 
of percent diameter stenosis in important interven- selected within a range of +-3 SD (0.3 mm), giving 
tional studies. confidence limits of 99 % .I32 lo4 
COMPARATIVE ASSESSMENT OF NEW DEVICES 
USING MLD AS THE CENTRAL MEASUREMENT 
New dilemmas have arisen as a result of the explo- 
sion of new interventional coronary treatments with 
respect to comparison of results, particularly long- 
term outcome. The unique mechanisms of action of 
and subsequent pathophysiologic responses to the 
various devices renders broad comparison of these 
treatment modalities basically invalid, especially be- 
cause it is generally recommended that atherectomy 
devices should not be used, nor should endoluminal 
stents be, implanted, in coronary vessels <3 mm in 
diameter. PTCA., however, can be (and is regularly) 
carried out in arteries <2 mm in size, and rotational 
atherectomy and excimer laser therapy are best 
suited to smaller vessels.132 
We consider that it may be reasonable to compare 
the effects of interventions in terms of their relative 
merits or by confining comparisons to matched 
lesions, i.e., lesions of similar severity, in vessel seg- 
ments of identical size and location (even though it 
has lately been demonstrated by our grouploo and 
others133 that, contrary to popular belief, restenosis 
rates are not significantly different throughout the 
coronary tree). .At the Thoraxcenter, facilities are 
available for the appropriate use of all of these ther- 
apeutic techniques. The increasingly widespread ap- 
plication of these devices, despite the lack of any hard 
evidence of greater long-term clinical benefit than 
balloon angioplasty, has prompted our search for a 
unifying descriptive approach to the assessment and 
comparison of immediate and long-term outcome 
between devices and has led to the serial develop- 
ment of two methods of comparing the theoretically 
incomparable. 
Comparing the immediate angiographic results of 
PTCA, directional coronary atherectomy (DCA), and 
intracoronary stenting with this technique illustrates 
that both DCA and stenting yield a more favorable 
early result than PTCA and that matching is a use- 
ful comparative method. lo3 Application of the match- 
ing principles to a direct comparison of immediate 
and long-term angiographic outcome after PTCA 
and DCA or stent implantation using cumulative 
distribution curves (Figs. 11 and 12),lo3s 135 is simi- 
larly rewarding in its clarity and simplicity. Because 
the lesions are matched for reference diameter, 
approximate overall improvement in luminal diame- 
ter (gain) at intervention and loss in minimal lumi- 
nal diameter during follow-up can be easily gleaned 
from the figure and directly compared. It is appreci- 
ated that although DCA is associated with a signifi- 
cantly greater initial gain (improvement) in MLD, 
the loss (restenosis) after DCA is also significantly 
greater than that after PTCA, so that the ultimate 
outcome (MLD at follow-up) is similar for both 
treatment modalities. This technique to compare 
immediate and long-term angiographic results after 
PTCA and self-expanding stainless steel stent im- 
plantation in 93 matched lesions has revealed that, 
although associated with a greater loss in luminal di- 
ameter during follow-up, stenting yields a signifi- 
cantly larger vessel lumen (reflected by a larger 
MLD) than PTCA at follow-up.io4 
Matching: A temporary but convenient surrogate for 
randomization. The first method enables us to actually 
compare the comparable by matching the lesions in 
each treatment group for severity, location, and ves- 
sel size, thereby defining a population in which any 
of the treatment modalities to be compared may rea- 
The matching process, by its principles, may be 
justifiably used at this time as a surrogate for 
randomized studies,lo4 facilitating otherwise invalid 
comparisons between interventions in relatively small 
patient groups. It is noteworthy that observations 
emerging from the matching of patients undergoing 
DCA and PTCA106 have been confirmed by prelim- 
inary results of the CAVEAT trial,l13 thus demon- 
strating a real and undeniable clinical use for this 
matching approach. Furthermore, superior angio- 
graphic results in terms of MLD at follow-up, of 
DCA, and of stenting over historical PTCA results as 
reported by Kuntz et a1,1223 124 are put in a slightly 
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Fig. 11. Cumulative frequency (distribution) curves to illustrate differential immediate (pre to post) and 
follow-up (post to follow-up) effects of PTCA versus directional coronary atherectomy (DCA) on matched 
coronary lesions with regard to absolute MLD measured by QCA. (From Umans VA et al. J Am Co11 Car- 
diol 1993;21:1382-90.) 
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Fig. 12. Immediate (pre to post) and long-term (post to follow-up) angiographic outcome of matched study 
in 93 patients having balloon angioplasty @A) or self-expanding stainless steel stent (St) implantation. 
Superior initial gain by stenting is somewhat counterbalanced by greater luminal loss during follow-up 
@up). Nevertheless, luminal diameter at follow-up remains significantly greater than for balloon 
angioplasty. (From de Jaegere P. J Am Co11 Cardiol 1992;19(suppl):277A.) 
different perspective by results obtained from match- 
ing. It is clear that the mean vessel size in patients 
treated by DCA and stent implantation are consid- 
erably greater (3.09 mm and 3.35 mm, respective- 
1~~~~) than in PTCA studies (2.6 mm)111,112. There- 
fore direct comparison of absolute angiographic re- 
sults obtained by these devices with those obtained 
by balloon angioplasty becomes somewhat irrelevant 
without either matching or normalizing for the indi- 
vidual vessel size, as described in the next section. 
The limitations of the basic matching approach to 
the comparison of interventianal therapies are, of 
course, that other potentially influential clinical and 
angiographic parameters are not taken into account 
in the matching process; therefore the effect of angi- 
nal status, medication, diabetes, lesion length, ec- 
centricity, calcification, etc. on the comparative out- 
come of the treatment modalities is ignored. How- 
ever, the matching study of stent implantation and 
balloon angioplasty lo4 addressed this issue of poten- 
tial disparity between patient groups with regard to 
these other variables and found no significant differ- 
ences in their distribution between the groups being 
compared. Furthermore, the matching comparison of 
balloon angioplasty with directional atherectomylo6 
also took account of age, gender, diabetes, and angi- 
nal status and found that this additional consider- 
ation did not affect the ultimate findings as already 
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Fig. 13. Scatter-histogram of all values obtained for relative gain after PTCA and relative loss (RL) dur- 
ing follow-up in large European multicenter restenosis prevention trial ‘I2 for both placebo and treatment 
groups. Linear relationship identical for both groups emerges, although coefficient of correlation is low at 
0.4. Full line, control group; dashed line, treatment group. 
described,lo7 thus perhaps vindicating the applica- 
tion of the simple basic angiographic matching prin- 
ciples used. 
Relative gain and relative loss in minimal luminal 
diameter. The second proposed method of compari- 
son of therapeutic devices arose originally from the 
need to create some type of sliding-scale criteria to 
circumvent the previously described limitations of 
the categoric loss ~0.72 mm criterion for assessing 
the outcome of balloon angioplasty in vessels of dif- 
ferent sizes. The concepts of relative gain and relative 
loss in MLD were therefore introduced to adjust lu- 
minal changes for individual vessel size by normaliz- 
ing the absolute change in ML.D after intervention 
and during follow-up for the reference diameter of 
the coronary segment in question54> 73$ 1oo-108 in a 
continuous approach. The net difference between 
relative gain and relative loss is termed the net gain 
index and is a measure of the ultimate net benefit of 
intervention. These simple calculations may be pre- 
sented as follows: Relative gain = MLD post inter- 
vention - MLD preintervention/vessel size; Relative 
loss = MLD post intervention - MLD at follow-up/ 
vessel size; and Net gain index = MLD at follow- 
up - MLD pre intervention/vessel size. 
The vessel size is represented by the interpolated 
reference diameter of the lesion before intervention 
because this is the closest possible objective angio- 
graphic approximation of the normal, disease-free 
vessel size. After intervention and at follow-up the 
interp,olated reference diameter is subject to greater 
potential for measurement variability as a direct 
consequence of the intervention and of the resteno- 
sis process, respectively, 38, 3g, 4o although there was no 
statistically significant difference in interpol’ated 
reference diameter between pre- and post-PTCA and 
at follow-up in the two previously mentioned Euro- 
pean multicenter restenosis prevention trials.rll, II2 
Kuntz et a1.123 previously presented a relationship 
between absolute gain at intervention and late loss 
during follow-up in their patients treated by direc- 
tional atherectomy and stent implantation. However, 
as a result of the wide variability in reference vessel 
size among lesions treatable by current interven- 
tional devices, we believe the application of relative 
gain and relative loss to be more appropriate and in- 
formative for comparative purposes. By using data 
accumulated prospectively during each of these res- 
tenosis prevention trials, we plotted the relative gain 
and relative loss values for all treated lesions and 
found a direct linear relationship between relative 
gain and relative loss (even though the coefficient of 
correlation was low at 0.4) for each patient popula- 
tion, with virtual superimposition of the regression 
lines for placebo and treatment groups in each trial 
(one of these trials is shown in Fig. 13; the other is 
practically identical). These graphic representations 
confirmed the outcome of the studies with regard to 
there being no demonstrable benefit of the agent un- 
der evaluation in terms of reduction in the loss in 
MLD during follow-up, as had been previously es- 
tablished by using cumulative distribution curves. 
Perhiaps more importantly, however, was the rela- 
tionship between relative gain and relative loss, 
which is not dissimilar from the relationship:demon- 
strated by Schwartz et ah6 between depth of vessel 
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Fig. 14. Relative gain and relative loss (on the Y axes) plotted against reference diameter in increments 
of 0.5 mm on the X axis. Parallel trend of decrease in both variables is observed with increasing reference 
diameter. 
wall injury and thickness of the subsequent neoin- 
timal hyperplasia in an experimental porcine model 
and that described by Kuntz et al. in their patients 
undergoing DCA or stent implantation. 
THE INFLUENCE OF VESSEL SIZE ON THE 
RESTENOSIS PROCESS 
Exploration of the relationship of the vessel size 
itself on the process of luminal renarrowing reveals 
that the relative loss (proportional loss of lumen 
during follow-up) decreases significantly as vessel 
size-increases in increments of 0.5 mm, as shown in 
Fig. 14. However, when it is similarly found that rel- 
ative gain shows a parallel pattern, it becomes 
evident that it is the relationship between relative 
gain and relative loss, as already described, that is of 
central importance to addressing the injury-hyper- 
plasia phenomenon from an angiographic viewpoint. 
When the relative gain-relative loss relationship was 
investigated according to these 0.5 mm increments of 
vessel diameter, it was apparent that the relationship 
was exactly similar for all vessels (Fig. 15). Thus what 
is described here appears to be a real phenomenon 
that is.independent of vessel size. We could speculate 
that the reason for the greater relative gain in small 
vessels is the result of the clinical requirement for a 
good angiographic result in the catheterization room. 
This demands considerable luminal gain in small 
vessels given the usual angiographic magnification 
limitations. In addition, perhaps balloon (or device) 
oversizing is more likely or frequent in small vessels. 
With the greater relative gain, more extensive wall 
injury is imparted, provoking a more intense healing 
response with formation of thicker neointimal layer 
that is reflected by greater angiographic relative loss 
in lumen during follow-up. This may be a simplistic 
but practical speculation on what is undoubtedly a 
complex and multifactorial phenomenon, but one 
message is clear: the inescapable fact that greater 
proportional luminal gain at intervention induces 
greater subsequent proportional loss during follow- 
UP. 
The restenosis paradox. This apparent paradox of 
greater luminal renarrowing associated with more 
substantial luminal improvement at balloon angio- 
plasty has now been demonstrated in several clinical 
studies from our group by multiple regression anal- 
ysis applied to large patient populations with respect 
to many potentially important predictors of resteno- 
sis.54> lo53 117,136 We have also examined the rela- 
tionship between relative luminal gain at inter- 
vention and relative loss during follow-up for other 
percutaneous coronary revascularization devices 
and preliminary results also demonstrate a direct 
linear relationship. lo1 In light of available evidence 
from previous clinical studies from our own institu- 
tionll-l&l& 9% 105 and othersl4>% 39,124, experiment& 
reports,65’ 13s and the commonly held belief that res- 
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Fig. 15. Linear regression of relative loss on relative gain according to increments af vessel size as shown 
in Fig. 14. Relationship between variables is similar for each group. It is also possible to glean two other 
messages from receding scatterplots with increasing vessel size: (1) much greater frequency with which bal- 
loon angioplasty procedures are carried out in smaller vessels, and (2) degree of relative gain achieved at 
balloon angioplasty is less in larger vessels, as shown in Fig. 14. 
tenosis is a tissue response to vessel wall injury, the 
demonstration of such a relationship between rela- 
tive luminal gain and loss is not all that surprising. 
The Mayo Clinic report65 (of a proportional neoint- 
imal response to graded vessel wall injury) observing 
that the extent of coronary’ artery injury was more 
closely related to the actual thickness of the neoint- 
imal layer than to percent luminal area stenosis 
highlights the impoitance in clinical angiographic 
restenosis studies of attempting to measure the vol- 
ume of the “doughnut” and the “doughtnut hole.” 
Collectively, all of these studies support previous ex- 
perimenta1137 and autopsy-based138 claims that the 
intensity of neointimal proliferation after balloon 
dilatation is dependent on the depth of vessel wall 
injury. Furthermore, they sustain the contention that 
categoric restenosis definitions are inherently limited 
in their ability to describe the ubiquitous process of 
luminal renarrowing after interventions. 
The deduction from the previously mentioned 
study by Kuntz et al. 124 that by achieving a greater 
gain in lumen newer devices may reduce angiographic 
restenosis, is apparently contradictory to our con- 
tention. Although our group focuses mainly on the 
relationship between the relative gain/relative loss 
relationship by which to judge the effectiveness of a 
therapeutic intervention as a reflection of its impact 
on the injary/hyperpla@ia relationship, Kuntz et al. 
focused on the final MLD at follow-up as the ultimate 
outcome variable. This is the difference, as has been 
succinctly put by Schwartz et a1.,65 between looking 
at the “doughnut” or the “doughnut hole.” There is 
little doubt that a larger lumen at follow-up is better 
for the patient and that this parameter, as discussed 
previously, is of paramount importance in assessing 
the long-term clinical success of therapy. However, in 
large clinical trials directed at prevention of the pro- 
ces.s of restenosis, the effect of therapy must be mea- 
sured by its ability to restrict or control the thickness 
of the doughtnut, which we believe is best encapsu- 
lated angiographically by the relative gain/relative 
loss relationship. In Fig. 16 the actual relative gain/ 
relative loss relationships of patients undergoing 
therapy by four different iriterventional devices are 
shown with the line of identity and an imagin&y re- 
gression line for the ideal interventional device3 is 
clear that a device whose regression line crosses the 
identity line can be considered to be associated with 
aworse angiographic outcome than one with a gentle 
line slope. The ideal device has a horizontal relation- 
ship between relative gain and loss such that despite 
increasing relative gain there is no increase in relative 
loss. Such a device may be considered as the magic 
bullet or golden flee’ce. This finding is in clear 
contrast to the published findings of Kuntz et 
a1.,131, 13g who h ave reported no difference in loss in- 
dex (acute gain/late loss) between patients treated by 
directional atherectomy, stent implantation, or bal- 
loon angioplasty and concluded that the most im- 
portant determinant of favorable long-term angio- 
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Fig. 16. Linear regression relationship of relative gain/ 
relative loss of patients who underwent therapy by four 
different interventional devices are shown with line of 
identity. Imaginary regression line for ideal interventional 
device is included. It is clear that device whose regres- 
sion line crosses identity line can be considered to be asso- 
ciated with worse angiographic outcome than one with 
gentle line slope. Ideal device has horizontal regression line 
slope so that with increasing relative gain there is no 
increase in relative loss. DCA, Directional atherectomy 
(n = 123 lesions); COIL, balloon-expandable tantalum coil 
stent (n = 101 lesions); MESH, self-expanding stainless 
steel mesh stent (n = 110 lesions); PTCA, percutaneous 
transluminal coronary (balloon) angioplasty (n = 1435 le- 
sions) .
graphic outcome is a large luminal diameter after in- 
tervention, regardless of which device is used to 
achieve this. It is worth noting that despite these 
apparently conflicting viewpoints, both the Beth 
Israelg4 and Thoraxcentre124 groups agree that in- 
stead of reducing intimal hyperplasia, newer devices 
actually provoke increased hyperplasia, and that the 
process of luminal renarrowing is a ubiquitous and 
normally distributed phenomenon and should be 
described as such rather than according to arbitrary 
binary criteria.g43 124 
Clinical implications and applications of relative gain 
and relative Wss. This direct relationship between 
restenosis, as represented by relative loss in luminal 
diameter during follow-up, and luminal improve- 
ment or relative gain at intervention, has important 
ramifications, not only for clinical trials but also per- 
haps for clinical decision making in individual pa- 
tients. With the impending widespread availability 
of quantitative coronary angiographic facilities for 
the catheterization room, precise measurements will 
be readily accessible on-line, allowing a step-by-step 
objective and accurate assessment of progress during 
intervention rather than the current practice of eye- 
balling the video screen with its inherent limitations. 
This should facilitate appropriate selection of bal- 
loon and device sizes to avoid excessive vessel wall 
injury caused by oversizing. As confirmed by the 
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considerable scatter of data points in the regression 
analyses shown in Figs. 13 and 15, the phenomenon 
of wall injury and healing response is clearly multi- 
factorial. In addition, it must be recognized that pro- 
gressively increasing relative gain will ultimately 
yield a greater proportional net angiographic benefit 
(despite provoking concomitantly greater relative 
luminal loss) because the relationship is always below 
and diverging from the line of identity. Therefore it 
would be fallacious to attempt to give individual 
guidelines as to the ideal relative gain for which to 
aim. In the final analysis, achievement of the great- 
est luminal improvement possible by the least trau- 
matic means and avoiding precipitation of acute 
complications must be the ultimate goal of percuta- 
neous intervention. 
The ultimate end-point. The ultimate test of new 
treatments is, of course, the randomized clinical trial, 
of which many are now in progress. The issues raised 
in this article identify a vital aspect of randomized 
trials, that is, how will the results be presented? As 
has been mentioned, angiographic endpoints are now 
evaluated by quantitative analysis in terms of changes 
in MLD from immediately after intervention to fol- 
low-up. The particular characteristic of the random- 
ized population is that baseline demographic and 
angiographic characteristics in the various treatment 
groups are assumed to be similar.135 However, the al- 
ready emphasized differences between devices with 
regard to the immediate luminal improvements at- 
tainable at intervention and the subsequent luminal 
loss during follow-up suggest that the within patient 
change in minimal luminal diameter may not be the 
measurement of choice to assess the comparative 
value of the various interventions. The most objec- 
tive and clinically meaningful parameter to use in 
rarzclomized clinical trials is the minimal luminal di- 
ameter at follow-up as the ultimate endpoint of 
treatment, taking all aspects of the trial into account. 
This simple approach may be equally usefully ap- 
plied to trials of pharmacologic agents for the control 
of restenosis. Change in MLD during follow-up is 
undoubtedly the clearest angiographic measure of 
the hyperplastic healing process, but it can only be 
usefully applied if, in addition to baseline clinical and 
angiographic features, luminal gain at intervention is 
also likely to be similar in the groups being compared 
thus where the same mechanical intervention is used. 
The therapeutic effectiveness of interventional de- 
vices in achieving satisfactory luminal increase with- 
out provoking excessive hyperplasia among different 
patient groups may best be assessed through com- 
parison of the relative gain/relative loss relationship 
(Fig. 16). The application of this approach to random- 
ized trials will provide its ultimate test of usefulness. 
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Conchsions. We submit, in agreement with others, 
that angiographic restenosis as a process of luminal 
renarrowing should be considered as a continuous 
phenomenon and be so described in clinical trials. In 
addition, a proportional relationship is described be- 
tween luminal increase at intervention and subse- 
quent renarrowing during follow-up for a number of 
interventional devices. It is clear therefore that res- 
tenosis is an unavoidable consequence of any therapy 
that inflicts injury on the arterial wall. In contrast to 
the findings of other groups, clear differences are ob- 
served between the devices in the relative gain/rela- 
tive loss relationship, which may reflect inherent de- 
vice-specific characteristics of the injury/hyperplasia 
phenomenon. We have no erudite solutions to offer to 
this persistent limitation of all interventional devices 
except to suggest that the search for a magic bullet 
now seems more compelling than ever. 
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